This paper reports that authors identify molecular patterns linked to primary resistance to VEN–HMA therapy, including a higher BCL‑XL/BCL‑2 ratio and frequent TP53 mutations. These findings point to potential therapeutic strategies worth exploring
Read more in depth 👉https://t.co/wmGENiPd1K
Our latest @Hemasphere_EHA study from @FIMM_UH defines key signatures of #venetoclax + hypomethylating agent #resistance in #AML and highlights strategies for targeting resistant disease.
Read more: https://t.co/EflicDst4Y
New findings from our VenEx trial in #AML: venetoclax resistance linked to altered apoptosis & PRAME overexpression. Exploring PRAME-targeted immunotherapy + apoptosis modulators. Grateful for Jane and Aatos Erkko Foundation support to advance this research. #JAES
1/4
Capillary Sampling Enables Venetoclax Concentration Measurement in Acute Myeloid Leukaemia Within Academic Multicentre Trial
New study by @LabKontro and colleagues – study highlights 👇
Ex vivo venetoclax sensitivity identified treatment responders and correlated with improved outcomes and prolonged survival. Groundbreaking results from the VenEx trial with the Finnish AML Group, @helsinkiuni and @FIMM_UH published now in @BloodJournal
VenEx trial showed that ex vivo drug sensitivity is beneficial for selecting patients with R/R or sAML for venetoclax-azacitidine therapy. https://t.co/IQpKqiLw1p #clinicaltrialsandobservations#myeloidneoplasia
Drug sensitivity testing on leukemia cells can predict how patients with acute myeloid leukemia (AML) will respond to a new combination therapy.
New @LabKontro results allow treatments to be tailored to those who are most likely to benefit.
📰@HUS_fi:
https://t.co/coAjWznMk1
Leukemiasolujen lääkeherkkyystestauksella voidaan ennustaa akuuttia myelooista leukemiaa sairastavien potilaiden hoitovaste uudelle lääkeyhdistelmälle.
@LabKontro tulokset mahdollistavat hoidon kohdentamisen siitä eniten hyötyville potilaille.
📰@HUS_fi: https://t.co/tYJl9GWFfO
Dr. Mika Kontro from @KontroLab discussed the latest advances in functional screening during the Multi-Omics Driven Precision Hematology Scientific Symposia at #ASH23. The VenEx trial indicates the efficacy of ex vivo venetoclax testing for predicting VEN+AZA responses in AML.
Meet our K. Albin Johansson Cancer Researcher @hkuusanm. Heikki has a versatile background in translational laboratory studies and focuses now on novel treatments for acute myeloid leukemia in @LabKontro. Read more 👇https://t.co/TbhJaJkNI9
A clinical trial performed in Finland has shown that a drug sensitivity test performed on patient's own cells in laboratory conditions predicts patient's response to a new effective leukemia drug, venetoclax. The study was led by Mika Kontro & @hkuusanm.
https://t.co/xxIUL1s6wz
1/ Excited to share our study with @ollidufva suggesting venetoclax resistance and BCL-XL dependence in erythroid/megakaryoblastic AML @BloodJournal
https://t.co/ktzWK6VxGT
Our newest paper "Ex vivo venetoclax sensitivity testing predicts treatment response in acute myeloid leukemia" is now published and accessible @Haematologica
https://t.co/qAhqtRMni3